Posted on 09/22/2014 10:29:08 AM PDT by BenLurkin
Mapp Biopharmaceutical, the company that makes ZMapp, says the drug's supplies are exhausted and that it takes months to make even a small batch.
With ZMapp unavailable, the hospital was looking into alternative medicines or the possibility of using blood serum from a cured patient, said Dr. Jose Ramon Arribas, of the Carlos III hospital.
Garcia Viejo is the second Spanish missionary to catch Ebola. Another priest, Miguel Pajares, 75, was flown back to Spain from Liberia on Aug. 7. Pajares began treatment with ZMapp, but died Aug. 12.
Ebola is blamed for the deaths of more than 2,600 people in West Africa.
(Excerpt) Read more at hosted.ap.org ...
OK, the time has come for the first outbreak here in the US.
I’m sure this problem can be solved by suing, prosecuting, or investigating the creators of ZMapp.
That it takes months to produce even a small batch is news. Apparently we won't be able to ramp production anytime soon if ever.
Maybe the vaccine will be ramp-able.
Funny this is revealed a day or two AFTER Americans are sent there.
The Army is well aware of all Ebola research and status on cures and preventions.
I would hope so, but that leaves questions.
Questions that you can’t even name?
So far you are batting a 1,000.
It would be funny, if the bidding was all public. I wonder how many millions of dollars individuals are offering for the stuff, while they fantasize about surviving and getting rid of all of the downscale trash.
You really are hostile. What do you think I did to you?
IRS audit.
Yes, we hope so. ZMapp is a treatment and doesn't appear to be scalable well at all. The vaccines being developed in Canada and Russia (maybe others) show much more promise for large scale and timely production. FDA licensing may be a problem.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.